Christopher Del Nagro

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell–mediated B-cell cytotoxicity

Ekkehard Mössner, Peter Brünker, Samuel Moser et al. · Blood · 2010 · 957 citations · Full text

Life Sciences, Immunology, Oncology +17

Metabolic plasticity underpins innate and acquired resistance to LDHA inhibition

Aaron Boudreau, Hans E. Purkey, A. Hitz et al. · Nature Chemical Biology · 2016 · 268 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +13

Depletion of the Central Metabolite NAD Leads to Oncosis-mediated Cell Death

Christopher Del Nagro, Yang Xiao, Linda Rangell et al. · Journal of Biological Chemistry · 2014 · 74 citations · Full text

Life Sciences, Biochemistry, Oncology +17

Identification of Preferred Chemotherapeutics for Combining with a <i>CHK1</i> Inhibitor

Judi Ramiscal, Kaska Kowanetz, Christopher Del Nagro et al. · Molecular Cancer Therapeutics · 2013 · 58 citations · Full text

Medicine, Oncology, Pharmacology +16

Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors

Solange Peters, Eric Angevin, Teresa Alonso‐Gordoa et al. · Clinical Cancer Research · 2024 · 13 citations

Pharmacy, Oncology, Pharmacology +17